Ocular cell therapy company OcuCell announced it has received seed funding from The Eye-Bank for Sight Restoration (EBSR). The funding will enable OcuCell to accelerate its mission of transforming the corneal cell therapy landscape through the development of cell therapy solutions that address critical ocular challenges, according to a company news release.
“We are thrilled to receive this strong vote of confidence from EBSR, who share our vision of a healthier future driven by cell therapy innovations,” OcuCell President and Co-Founder Chris Stoeger said in the news release. “This funding will be instrumental in moving new therapies forward and bringing our transformative cell technologies closer to the patients who need them.”
OcuCell also announced the appointment of Patricia Dahl, CEO and Executive Director of EBSR, to OcuCell's board of directors.
“It is The Eye-Bank for Sight Restoration’s longtime mission to support pioneering scientific research and innovative medical techniques that will provide sight restoring cures and treatment for blindness," Ms. Dahl said in a the news release. "The Eye-Bank's Board of Directors recognizes the importance of moving cellular therapies forward and welcomes the opportunity to help advance OcuCell’s efforts to fruition.”
EBSR was founded as the world’s first eye bank in 1944 by ophthalmologist and corneal surgeon, R. Townley Paton, MD, and has a long history of investment in sight restoration initiatives, according to OcuCell.
OcuCell is actively seeking to collaborate with industry stakeholders, research institutions, and healthcare partners to bring transformative cell therapy technologies to the forefront of ocular healthcare.
Comments